Related Experiment Video
Updated: Jul 25, 2026
Efficient Recombinant Parvovirus Production with the Help of Adenovirus-derived Systems
Published on: April 23, 2012
Potentiation of a recombinant oncolytic parvovirus by expression of Apoptin
S Olijslagers1, A Y Dege, C Dinsart
1Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, The Netherlands.
Abstract:
The oncotropic and oncolytic behaviors of certain autonomous rodent parvoviruses make them promising vectors for anticancer gene therapies. However, these parvoviruses are often not potent enough to kill all tumor cells equally well. With the aim of enhancing the intrinsic antitumor effect and the range of natural parvoviruses, a recombinant H1 parvovirus vector was constructed that produces the Apoptin protein, a tumor cell-specific, p53-independent, Bcl-2-insensitive apoptotic effector. We compared the apoptotic activity exerted by a recombinant hH1/Apoptin virus with that of a Green Fluorescent Protein (GFP)-transducing recombinant virus, hH1/GFP, in three human tumor cell lines differing in their susceptibility to wild-type parvovirus H1-induced killing. We found that in cells that were rather resistant to the basal cytotoxic effect of wild-type H1 or the GFP recombinant virus, a parvovirus that expressed Apoptin caused a pronounced, additional cytotoxic effect. In contrast to its enhanced cytotoxicity toward tumor cells, hH1/Apoptin virus was not more toxic to normal human fibroblasts than was the wild-type H1 virus. Taken together, these data indicate that enhancing the oncotropic behavior of wild-type H1 parvoviruses with the tumor-specific apoptotic potency of Apoptin should lead to an effective replicative parvoviral vector.
Insights
Researchers engineered a parvovirus to deliver the Apoptin protein, enhancing its tumor-killing ability without harming normal cells. This modified virus shows promise as a potent anticancer gene therapy vector.
Area of Science:
- Oncology
- Virology
- Gene Therapy
Background:
- Rodent parvoviruses exhibit oncotropic and oncolytic properties, making them potential anticancer gene therapy vectors.
- Current parvovirus vectors often lack sufficient potency for complete tumor cell eradication.
- Apoptin is a tumor cell-specific protein that induces apoptosis independently of p53 and Bcl-2.
Purpose of the Study:
- To enhance the antitumor efficacy and tumor cell targeting range of natural parvoviruses.
- To create a recombinant H1 parvovirus vector expressing the Apoptin protein.
- To evaluate the enhanced apoptotic activity and tumor specificity of the hH1/Apoptin virus.
Main Methods:
- Construction of a recombinant H1 parvovirus vector expressing Apoptin (hH1/Apoptin).
- Comparison of hH1/Apoptin with a control recombinant virus (hH1/GFP) expressing Green Fluorescent Protein.
- Assessment of cytotoxic and apoptotic activity in three human tumor cell lines with varying susceptibility to wild-type parvovirus H1.
Main Results:
- The hH1/Apoptin virus demonstrated a significant additional cytotoxic effect in tumor cells resistant to wild-type H1 or hH1/GFP.
- Enhanced tumor cell killing was observed without increased toxicity to normal human fibroblasts compared to wild-type H1.
- Apoptin expression potentiated the oncolytic behavior of the parvovirus vector.
Conclusions:
- Combining the oncotropic nature of H1 parvovirus with Apoptin's tumor-specific apoptotic function creates a potent oncolytic vector.
- The hH1/Apoptin virus represents a promising replicative parvoviral vector for enhanced anticancer gene therapy.
- This strategy offers improved tumor cell killing with maintained safety for normal tissues.
